Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 7/20 | 0.64 |
| ▸ | GSK3B | P49841 | 3/20 | 0.58 |
| ▸ | GSK3A | P49840 | 1/20 | 0.58 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.54 |
| ▸ | CSF1R | P07333 | 1/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.54 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.54 |
| ▸ | LTK | P29376 | 1/20 | 0.54 |
| ▸ | KDR | P35968 | 1/20 | 0.54 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.54 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.54 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.54 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.54 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.54 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.54 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.54 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.54 |
| ▸ | PDPK1 | O15530 | 6/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6479380 | 0.91 | JAK2 (0.58) | JAK2GSK3BGSK3AAURKBMAP4K4 | |
| SCHEMBL3361082 | 0.86 | JAK2 (0.57) | JAK2GSK3BGSK3AAURKBMAP4K4 | |
| SCHEMBL6489615 | 0.82 | PDPK1 (0.53) | JAK2GSK3BFGFR1PDPK1JAK1 | |
| SCHEMBL6488370 | 0.82 | IKBKE (0.57) | JAK2GSK3BGSK3AKDM4EGAA | |
| SCHEMBL6491284 | 0.80 | IKBKE (0.58) | JAK2GSK3BGSK3AKDM4EGAA | |
| SCHEMBL16493511 | 0.78 | GSK3B (0.48) | JAK2GSK3BGSK3AAURKBMAP4K4 | |
| SCHEMBL6490350 | 0.78 | GSK3B (0.60) | JAK2GSK3BFGFR1PDPK1CYP3A4 | |
| SCHEMBL3359889 | 0.78 | JAK2 (1.00) | JAK2GSK3BGSK3AAURKBMAP4K4 | |
| SCHEMBL3361070 | 0.78 | JAK2 (1.00) | JAK2GSK3BGSK3AAURKBKDR | |
| SCHEMBL12907246 | 0.78 | JAK2 (1.00) | JAK2GSK3BGSK3AAURKBMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949579-B2 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2005-09-27 | — | — | US | claimed |
| US-20040014802-A1 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2004-01-22 | — | — | US | claimed |
| EP-1487804-B1 | AMINOINDAZOLE DERIVATIVES AS PROTEIN-KINASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2014-02-26 | — | — | EP | disclosed |
| US-6949579-B2 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2005-09-27 | — | — | US | disclosed |
| US-20040014802-A1 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014802-A1 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | CYP2C8, NR0B2, NR2C2 | JAK2 1774/4885GSK3B 2342/4885GSK3A 2830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.